Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Baxter Gains SFDA Approval for Recombinant Hemophilia Treatment

publication date: May 17, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Baxter International has received approval from the SFDA of its treatment for hemophilia A, a product known as Advate. Advate is a recombinant human coagulation factor VIII for injection used both for control and prevention of bleeding in individuals with hemophilia A. According to Baxter, more than 50,000 people in China have hemophilia A. More details....

Stock Symbol: (NYSE: BAX)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...